BiotechTube
PrimeGen US

PrimeGen US

Irvine, United States· Est.
primegenus.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

PrimeGen US is a private, pre-clinical stage biotech founded in 2005 and headquartered in Irvine, California. The company is developing activated mesenchymal stem cell (MSC) therapies using its patented StemXcell™ platform, which pre-programs MSCs to counteract inflammation. Its lead programs target inflammatory liver diseases, with preparations underway for FDA-authorized clinical trials. The company operates as a therapeutics developer and is currently pre-revenue.

Inflammatory DiseasesLiver DiseasesAutoimmune Diseases

Technology Platform

StemXcell™ Activation Platform: A proprietary technology that pre-activates mesenchymal stem cells (MSCs) using disease-specific pro-inflammatory signals to enhance their immunomodulatory potency for targeted anti-inflammatory therapy.

Opportunities

The massive and growing unmet need in NASH and liver disease, with no approved pharmacologic therapies for NASH, presents a multi-billion dollar market opportunity.
Success in liver disease could validate the StemXcell™ platform for rapid expansion into other high-prevalence inflammatory and autoimmune conditions.

Risk Factors

High scientific risk as the novel activation platform is unproven in humans.
Significant regulatory and manufacturing complexities associated with cell therapy development.
Intense competition in the liver disease therapeutic landscape from numerous drug and cell therapy developers.

Competitive Landscape

PrimeGen competes in the crowded NASH/therapeutic space against large pharma and biotech firms developing small molecules, biologics, and other cell therapies. Its differentiation lies in its patented MSC activation platform aiming for targeted, potent immunomodulation, but it faces competition from other MSC-based therapy developers and a wide array of mechanistic approaches.

More companies in Cell & Gene Therapy →More companies in United States →